View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
January 30, 2019updated 03 Dec 2018 4:34pm

Industry Viewpoints: Patient Recruitment and Expanded Access

In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges of patient recruitment

Elizabeth Williams: Can you provide an insight into the current challenges you face in clinical operations in oncology?

Howard Fingert: The challenges range from how to align working practices and SOPs (standard operating procedures) among various regions and stakeholders. At Takeda , we do a fair number of global trials, so it’s vital to stay to avoid the speed bumps that can come your way.

EW: A recurring challenge seems to be patient recruitment – can you shed any light on any innovation taking place in this area?

HF: There are numerous innovations taking place in the clinical trial space that’s making patient recruitment easier to deal with. Two examples include real world evidence and expanded access. A recent issue of the Journal of Clinical Oncology was dedicated to expanded access, the idea of bringing in more patients who were previously excluded, namely, the elderly or those with HIV, into clinical trials. If this happens then how do you manage patients in terms of quality and operations?

EW: How can this issue be remedied in that case?

HF: So, for instance, patients with HIV are often totally excluded from studies, however, there’s no valid reason to exclude. Operationally, expanded access is a good thing as one of the goals of operations is to increase enrolment metrics. If you broaden the inclusion criteria it will support a larger trial. However, sponsors are still unwilling to commit to expanded access, due to the potential implications it may have on data generation.

EW: Who’s currently leading the way in that regard?

HF: The National Cancer Institute (NCI ) are really committed to doing these things for the greater good of patients by researching experimental treatments. For patients who don’t meet the inclusion criteria, or patients with HIV and other previously excluded conditions, the only way to get access is to try something very novel.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena